Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3354866 | 0.98 | CA1 (0.38) | CA1CA2HDAC1HDAC2CHRM1 | |
| SCHEMBL2810383 | 0.87 | CA2 (0.50) | CA1CA2MMP9TP53SLC1A3 | |
| SCHEMBL15110520 | 0.85 | TP53 (0.47) | CA1CA2TP53GRIK1SLC1A2 | |
| SCHEMBL29211666 | 0.84 | TP53 (0.46) | CA1CA2TP53GRIK1GRIK2 | |
| SCHEMBL10693782 | 0.82 | GABRR1 (0.38) | CA1CA2PMP22 | |
| SCHEMBL27399020 | 0.82 | HDAC1 (0.41) | CA1CA2HDAC1HDAC2CHRM1 | |
| SCHEMBL1287927 | 0.82 | CHRM1 (0.41) | CA1CA2HDAC1HDAC2CHRM1 | |
| SCHEMBL5503 | 0.81 | CA1 (0.37) | CA1CA2PMP22 | |
| SCHEMBL2811963 | 0.80 | ANPEP (0.33) | PMP22 | |
| Hydrochloric Acid SCHEMBL8710294 | 0.79 | CA1 (0.35) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004502669-A | — | — | 2004-01-29 | — | — | JP | claimed |
| EP-1353898-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| US-20230121768-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2022-08-09 | — | — | US | disclosed |
| WO-2019038362-A1 | ANTIBACTERIAL PYRROLOIMIDAZOLONES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-28 | — | — | WO | disclosed |
| US-20180354918-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2018-12-13 | — | — | US | disclosed |
| US-20160002185-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2958902-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20140024690-A1 | Isoxazole Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2683689-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. | 2012-10-11 | — | — | US | disclosed |
| WO-2012137099-A1 | IMIDAZOLE, PYRAZOLE, AND TRIAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012137094-A1 | ISOXAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012120397-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | MLLT1, BMI1, DOT1L | CA1 2209/4885CA2 2140/4885HDAC1 38/4885 |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, LCT, HAX1 | CA1 2504/4885CA2 2300/4885HDAC1 53/4885 |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | CA1 2035/4885CA2 1239/4885HDAC1 72/4885 |
| US-20180354918-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, MDM4 | CA1 1558/4885CA2 1782/4885HDAC1 975/4885 |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | MDM2, TP53, MDM4 | CA1 1558/4885CA2 1782/4885HDAC1 975/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | CA1 4880/4885CA2 4741/4885HDAC1 878/4885 |
| US-20230121768-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | MLLT1, BMI1, DOT1L | CA1 2209/4885CA2 2140/4885HDAC1 38/4885 |
| US-20160002185-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, MDM4 | CA1 1671/4885CA2 1777/4885HDAC1 990/4885 |
| US-20140024690-A1 | Isoxazole Derivatives Useful As Antibacterial Agents | HAX1, PRXL2A, PRDX1 | CA1 3703/4885CA2 1352/4885HDAC1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.